A phase II evaluation of AMG 706 [motesanib] (IND 79,697) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

12 Dec 2017 Status changed to discontinued due severe toxicity causing concern for patients
29 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
29 Apr 2011 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com